Immunotherapy company Enlivex Therapeutics (NASDAQ: ENLV) share price has staged a strong rally after the company announced positive results from its clinical trial of Allocetra in COVID-19 patients who are in a severe/critical condition.
The trial included five patients, three in a severe condition and two in a critical condition, with all five recovering and discharged from hospital.
Prof. Dror Mevorach, M.D., Chief Scientific and Medical Officer of Enlivex, said that the results “represent a unique opportunity for Enlivex to contribute towards efforts aimed at combating the ongoing global COVID-19 pandemic. Importantly, the initial positive results seen in sepsis patients treated with Allocetra are consistent with those observed in COVID-19 patients in severe and critical condition.”
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Enlivex said it will now move on to a more extensive Phase 2 clinical trial of coronavirus patients in severe or critical condition and will be working on the recruitment of additional patients.
“Enlivex will continue to work towards efforts aimed at combating the ongoing global COVID-19 pandemic, while continuing to execute our sepsis clinical development program. The cumulative clinical data to date from the clinical trials in sepsis and COVID-19 are in line with our expectations,” said the company’s CEO Oren Hershkovitz.
Source: TipRanks
The news has seen Enlivex’s stock price jump over 102% premarket on Thursday to $12 per share.
Based on one analyst surveyed by TipRanks, there could be further upside in-store with a target of $22 over the next 12 months, representing a potential 270% increase from yesterday’s closing price of $5.94.
PEOPLE WHO READ THIS ALSO VIEWED:
